| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75b86e50a7529f6158517db14a0b81df |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4742
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96494
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-18 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2019-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9de3fcedd1f08dc23ea44ca1e74abc5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0eeebafec78958a59a8c7674ccbab64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f778b7feca7ad4eeb24816a205987afd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c523ec69f22421b33a40fd885cd1d3db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28458fc318695d17f2be8ea62ac7046d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07f370b17ca7279366c06a459715662c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fdae34f6fa481b95ddb8143401f5b31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_512eba3f34cbb773fa1e52c94a083477
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbb16eb127a06490a90ba64702c75d35 |
| publicationDate |
2019-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019197200-A1 |
| titleOfInvention |
Methods, uses and kits for monitoring or predicting response to periodontal disease treatment |
| abstract |
Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Interleukin-1-beta (IL-1β) and 5 Matrix metalloproteinase-8 (MMP-8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of 10 periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal treatment status in said patient. |
| priorityDate |
2018-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |